These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prognostic value of metabolic tumour volume on baseline Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463 [TBL] [Abstract][Full Text] [Related]
3. Prediction of Overall Survival and Progression-Free Survival by the Zhou Y; Ma XL; Pu LT; Zhou RF; Ou XJ; Tian R Contrast Media Mol Imaging; 2019; 2019():5963607. PubMed ID: 31777473 [No Abstract] [Full Text] [Related]
4. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma. Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the prognostic values of Lim CH; Hyun SH; Moon SH; Cho YS; Choi JY; Lee KH Sci Rep; 2020 Jul; 10(1):12748. PubMed ID: 32728134 [TBL] [Abstract][Full Text] [Related]
7. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma]. Ding CY; Guo Z; Sun J; Yang WP; Li TR Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362 [No Abstract] [Full Text] [Related]
8. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma. Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875 [TBL] [Abstract][Full Text] [Related]
9. Can pretreatment Song H; Jiao Y; Wei W; Ren X; Shen C; Qiu Z; Yang Q; Wang Q; Luo QY Eur Radiol; 2019 Jul; 29(7):3945-3954. PubMed ID: 30859285 [TBL] [Abstract][Full Text] [Related]
10. F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma. Gallicchio R; Mansueto G; Simeon V; Nardelli A; Guariglia R; Capacchione D; Soscia E; Pedicini P; Gattozzi D; Musto P; Storto G Eur J Haematol; 2014; 92(5):382-9. PubMed ID: 24428392 [TBL] [Abstract][Full Text] [Related]
11. Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma. Li X; Sun X; Li J; Liu Z; Mi M; Zhu F; Wu G; Lan X; Zhang L Cancer Med; 2019 Sep; 8(11):5012-5022. PubMed ID: 31293092 [TBL] [Abstract][Full Text] [Related]
12. Prognostic role of baseline Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563 [TBL] [Abstract][Full Text] [Related]
13. Serum level of soluble interleukin-2 receptor is positively correlated with metabolic tumor volume on Senjo H; Kanaya M; Izumiyama K; Minauchi K; Hirata K; Mori A; Saito M; Tanaka M; Iijima H; Tsukamoto E; Itoh K; Ota S; Morioka M; Hashimoto D; Teshima T; Cancer Med; 2019 Mar; 8(3):953-962. PubMed ID: 30790452 [TBL] [Abstract][Full Text] [Related]
14. Prognostic parameters on baseline and interim [ 18 F]FDG-PET/computed tomography in diffuse large B-cell lymphoma patients. Czibor S; Carr R; Redondo F; Auewarakul CU; Cerci JJ; Paez D; Fanti S; Györke T Nucl Med Commun; 2023 Apr; 44(4):291-301. PubMed ID: 36705233 [TBL] [Abstract][Full Text] [Related]
16. Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma. Decazes P; Becker S; Toledano MN; Vera P; Desbordes P; Jardin F; Tilly H; Gardin I Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1672-1679. PubMed ID: 29705879 [TBL] [Abstract][Full Text] [Related]
17. Tumour necrosis as assessed with Kahle XU; Hovingh M; Noordzij W; Seitz A; Diepstra A; Visser L; van den Berg A; van Meerten T; Huls G; Boellaard R; Kwee TC; Nijland M Eur Radiol; 2019 Nov; 29(11):6018-6028. PubMed ID: 31028445 [TBL] [Abstract][Full Text] [Related]
18. FDG PET/CT response in diffuse large B-cell lymphoma: Reader variability and association with clinical outcome. Han EJ; O JH; Yoon H; Jung SE; Park G; Choi BO; Cho SG Medicine (Baltimore); 2016 Sep; 95(39):e4983. PubMed ID: 27684851 [TBL] [Abstract][Full Text] [Related]
19. The clinical value of texture analysis of dual-time-point Nakajo M; Jinguji M; Aoki M; Tani A; Sato M; Yoshiura T Eur Radiol; 2020 Mar; 30(3):1759-1769. PubMed ID: 31728684 [TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma. Tateishi U; Tatsumi M; Terauchi T; Ando K; Niitsu N; Kim WS; Suh C; Ogura M; Tobinai K Cancer Sci; 2015 Feb; 106(2):186-93. PubMed ID: 25495273 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]